Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

• Main Authors: Yuru Nie (Author), Weiqing Lu (Author), Daiyu Chen (Author), Huilin Tu (Author), Zhenling Guo (Author), Xuan Zhou (Author), Meifang Li (Author), Sanfang Tu (Author), Yuhua Li (Author)
• Formato: Livro
• Publicado em: BMC, 2020-05-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up p...